IBD, intestinal inflammation, microbiota, neutrophil Inflammatory bowel disease (IBD) is a chronic inflammatory condition with increasing prevalence.Current therapies are only partially efficient and associated with potentially severe side effects, highlighting the need for innovative therapeutic strategies.Here, we explored the novel dialogue between neutrophils and microbiota in intestinal homeostasis and inflammation, opening a promising avenue for IBD management. 1 IBD is complex, resulting from genetic predisposition, alterations of the gut microbiota, and environmental factors. 2 Unlike auto-inflammatory diseases caused by the spontaneous over-activation of inflammatory pathways, IBD often involves loss-of-function mutations.Deficient innate immune responses, including defects in the intestinal epithelial barrier, fail to control the altered intestinal microbiota, triggering more activation of the adaptive immune system and leading to chronic inflammation and tissue damage.3 For example, a loss-of-function mutation in the gene NOD2, encoding an innate immunity sensor of bacterial wall components, is associated with Crohn's disease, 4 whereas a gain-of-function mutation in the same gene causes Blau syndrome.Neutrophil infiltration into the intestinal mucosa is a hallmark of active IBD, with calprotectin and other neutrophil granule proteins as key faecal biomarkers.